A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

The earliest they are likely to become available is around summer, after drug pricing has been finalized. These products will be covered by the public health insurance system. The out-of-pocket burden ...

Japanese government experts endorsed on Thursday ground-breaking projects to manufacture regenerative medicine products to ...

Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Shares of Japan's Sumitomo Pharma fell over 15% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.

Japan's Health, Labor and Welfare Minister Kenichiro Ueno said Friday that approval will likely be given soon on the two regenerative medical products derived from induced pluripotent stem (iPS) cells ...

Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products prepared from iPS cell ...

TOKYO, Feb 19 (Reuters) - Japan's health ministry said on Thursday a panel of specialists had endorsed Sumitomo Pharma's iPS cell-derived treatment for Parkinson's disease, paving the way for the ...

Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson's disease Japan's health ministry panel on Thursday approved the ...

Induced pluripotent stem cells (iPS cells) can be created from any tissue in the human body and possess the ability to transform into a wide range of tissues. Kobe University MARUYAMA Tatsuo and his ...

TOKYO, Japan - Japanese government experts endorsed on Thursday ground-breaking projects to manufacture regenerative medicine ...